Recent Company News

• 02:53 AM ET May 12, 2026
  

  Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?

• 07:40 AM ET Apr 30, 2026
  

  Barinthus Biotherapeutics reports Q1 EPS ($0.14) vs FactSet ($0.28) [1 est] ($0.60, 0.00)

• 04:33 PM ET Apr 22, 2026
  

  Barinthus Biotherapeutics discloses appointment of Douglas Swirsky as CFO, effective 1-May ($0.63, 0.00)

• 08:04 AM ET Mar 13, 2026
  

  Barinthus Biotherapeutics reports FY EPS ($1.64) vs FactSet ($1.50) [2 est, ($1.77)-(1.23)]

• 06:22 AM ET Feb 23, 2026
  

  Barinthus Biotherapeutics amends merger agreement with Clywedog - 8-K ($0.63, 0.00)

• 08:03 AM ET Dec 10, 2025
  

  Barinthus Biotherapeutics announces update on Phase 1 Avalon clinical trial of VTP-1000 for the treatment of Celiac disease ($0.68, 0.00)

• 07:35 AM ET Nov 07, 2025
  

  Barinthus Biotherapeutics reports Q3 EPS ($0.36) vs FactSet ($0.40) [2 est, ($0.45)-(0.34)] ($1.19, 0.00)

• 11:14 AM ET Oct 06, 2025
  

  StreetAccount M&A Summary: Week of 29-Sep

• 08:07 AM ET Sep 30, 2025
  

  Barinthus Biotherapeutics to combine with Clywedog Therapeutics in all-stock transaction ($1.48, 0.00)